Competition in the obesity drug sector is intensifying rapidly
The program may not be the right fit for anyone who requires in-person clinical evaluation, anyone outside the eligible state list, anyone uncomfortable with the non-refundable consultation policy, or anyone whose medical history may be excluded under the published criteria
What symptoms should prompt me to seek urgent advice
These drugs, initially developed for diabetes, have demonstrated significant weight loss benefits, positioning them as key players in the fight against obesity
Common risks shared with all GLP-1 medications include gastrointestinal side effects - nausea, vomiting, diarrhea, constipation - especially when starting or increasing dose
While the medication begins working in the body soon after the first dose, noticeable appetite suppression usually develops gradually over the first few weeks